Overactive Bladder

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research
  12. References
  13. Connections
  14. Featured Videos

1. Overview

Overactive Bladder (OAB) is a clinical syndrome defined by the International Continence Society (ICS) as urinary urgency, usually accompanied by increased daytime frequency (eight or more voids per day) and/or nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology. The cardinal symptom is urgency — a sudden, compelling desire to void that is difficult to defer — which distinguishes OAB from simple urinary frequency or stress incontinence.

OAB is subclassified into two phenotypes based on the presence or absence of leakage: OAB-wet (urgency with urge incontinence) and OAB-dry (urgency without incontinence). OAB-wet carries greater quality-of-life burden and is more commonly the presenting complaint driving patients to seek care. Approximately 16% of adults in the general population fulfill symptomatic criteria for OAB, making it one of the most prevalent lower urinary tract conditions worldwide.

2. Epidemiology

Overactive bladder affects an estimated 33 million adults in the United States, with prevalence rising markedly with advancing age. The NOBLE (National Overactive Bladder Evaluation) program and subsequent national surveys consistently demonstrate that approximately 16% of adults over age 18 report OAB symptoms, a figure that increases to 40% of women and 30% of men over age 75. Despite this high prevalence, fewer than half of affected individuals seek medical attention, largely due to embarrassment, acceptance of symptoms as a normal consequence of aging, or unawareness that effective treatments exist.

Sex-specific epidemiology differs by symptom subtype: OAB-wet is more prevalent in women across all age groups, while urgency frequency without incontinence is roughly equally distributed between sexes. In men, OAB commonly coexists with bladder outlet obstruction from benign prostatic hyperplasia (BPH), complicating both diagnosis and management. Globally, the National Community Prevalence of Overactive Bladder study estimated that approximately 11% of men and 12.8% of women across five countries fulfill OAB criteria, with the United States reporting among the highest rates.

3. Pathophysiology

The pathophysiology of OAB centers on abnormal detrusor muscle activity and altered afferent bladder signaling, though the precise mechanisms remain incompletely understood.

Detrusor Overactivity

Urodynamically, OAB frequently (though not invariably) correlates with detrusor overactivity (DO) — involuntary phasic contractions of the detrusor muscle during the filling phase of the micturition cycle, occurring at a pressure exceeding 6–15 cmH2O. DO is classified as neurogenic (arising from identifiable neurological disease, such as stroke, multiple sclerosis, or spinal cord injury) or idiopathic (occurring in the absence of demonstrable neurological or local pathology). The majority of OAB cases are idiopathic.

M3 Muscarinic Receptor Signaling

Detrusor smooth muscle contraction is mediated predominantly through M3 muscarinic acetylcholine receptors, which couple to Gq proteins, activate phospholipase C, and increase intracellular calcium via IP3-mediated release from the sarcoplasmic reticulum. In OAB, spontaneous acetylcholine release from detrusor myocytes (the "myogenic hypothesis") or heightened muscarinic receptor sensitivity generates propagated detrusor contractions during the filling phase. M3 receptor subtype selectivity is the pharmacological rationale underlying antimuscarinic drug development.

Urothelial Afferent Pathway

The urothelium is now recognized as an active sensory and signaling structure, not merely a passive barrier. In response to stretch during bladder filling, urothelial cells release adenosine triphosphate (ATP), acetylcholine, nitric oxide, and substance P, which activate purinergic P2X3 receptors and transient receptor potential (TRP) channels on subepithelial afferent C-fibers and A-delta fibers. In OAB, enhanced urothelial ATP release and upregulated TRP channel expression (especially TRPV1 and TRPA1) amplify afferent urgency signaling before physiologic bladder capacity is reached.

Pudendal and Tibial Nerve Roles

Sacral spinal cord circuits integrating afferent input from the bladder and somatic input from the pudendal nerve modulate the micturition reflex. The tibial nerve (L4–S3 root origin), which carries somatic afferents to the same sacral segments that control bladder function, provides the anatomical rationale for percutaneous tibial nerve stimulation (PTNS) as a neuromodulatory OAB treatment. Dysfunction of descending inhibitory control from the pontine micturition center (PMC) and prefrontal cortex contributes to urgency in both neurogenic and idiopathic OAB.

4. Etiology and Risk Factors

5. Clinical Presentation

The four cardinal symptoms of OAB form the ICS-defined symptom complex:

Validated Assessment Tools

6. Diagnosis

OAB is a clinical diagnosis based on symptom criteria. The AUA/SUFU guideline emphasizes ruling out reversible causes before initiating treatment.

Urinalysis and Urine Culture

Urinalysis with microscopy is the essential first-line test to exclude urinary tract infection (UTI) as a reversible cause of urgency and frequency. Pyuria with bacteriuria warrants culture and targeted antibiotic therapy. Microscopic hematuria (more than 3 red blood cells per high-power field on two of three properly collected specimens) mandates urological evaluation to exclude bladder malignancy before attributing symptoms to OAB.

Post-Void Residual (PVR) Measurement

Bladder ultrasound or in-and-out catheterization to measure PVR is recommended to exclude urinary retention and incomplete bladder emptying, which can mimic OAB symptoms. A PVR exceeding 150–200 mL indicates impaired bladder emptying and alters the management approach, particularly before initiating anticholinergic medications that further impair detrusor contractility.

Urodynamics

Multichannel filling cystometry is the gold-standard method for demonstrating detrusor overactivity — phasic involuntary detrusor contractions during bladder filling. Urodynamic evaluation is indicated when the diagnosis is uncertain, when empiric therapy has failed, when neurological disease is present, or when invasive therapy (neuromodulation, botulinum toxin, surgery) is planned. Urodynamic DO is identified in approximately 60–70% of patients with symptomatic OAB, but its absence does not exclude OAB, and its presence in asymptomatic individuals does not establish the diagnosis.

Cystoscopy

Not required for routine OAB evaluation but indicated when hematuria is present, when bladder pathology (carcinoma in situ, bladder stones, foreign body) must be excluded, or when Hunner lesions of interstitial cystitis are suspected on clinical grounds. Cystoscopy findings in uncomplicated OAB are typically normal.

7. Treatment

The AUA/SUFU OAB guideline recommends a stepwise treatment approach, beginning with least-invasive interventions and escalating based on response and patient preference.

First-Line: Behavioral Therapies

Second-Line: Pharmacotherapy

Two pharmacological classes with distinct mechanisms are available for OAB:

Third-Line: Neuromodulation

Fourth-Line: OnabotulinumtoxinA Intradetrusor Injection

OnabotulinumtoxinA (100 U for non-neurogenic OAB; 200 U for neurogenic OAB) is injected into multiple detrusor sites via cystoscopic guidance under local or general anesthesia. The toxin cleaves SNAP-25 synaptosomal protein, blocking vesicular acetylcholine release from efferent motor terminals and impairing afferent ATP/substance-P release from urothelial sensory fibers. Randomized trials demonstrate 60–70% reduction in urgency incontinence episodes, with approximately 30% of patients achieving complete continence. Duration of effect is 6–12 months, necessitating repeat injections. Urinary retention requiring clean intermittent self-catheterization occurs in 6–12% of patients with non-neurogenic OAB at the 100 U dose; patients must be counseled on and capable of self-catheterization before treatment.

8. Complications

9. Prognosis

OAB is a chronic condition that follows a fluctuating course but rarely resolves completely without active management. Approximately 60–70% of patients achieve significant symptom improvement with combined behavioral and pharmacological therapy, and response rates are higher when treatments are combined rather than used sequentially. Behavioral therapy alone produces durable benefit in 50–80% of motivated patients who complete structured programs.

Sacral neuromodulation (SNM) offers the most durable long-term outcomes among procedural options: the ROSETTA trial demonstrated sustained 50% symptom reduction at 24 months in approximately 60% of implanted patients. Approximately 30% of SNM patients achieve complete continence. OnabotulinumtoxinA provides substantial relief with a 6–12 month durability that requires planned repeat injections; sustained benefit over multiple injection cycles is well-documented. Overall, fewer than 10% of patients require major reconstructive surgery for OAB.

Prognosis is less favorable when OAB is secondary to progressive neurological disease (MS, Parkinson's), where symptomatic control must be managed alongside the underlying condition's trajectory. Elderly patients with cognitive impairment face additional challenges due to limited pharmacotherapy options and difficulties adhering to behavioral regimens.

10. Prevention

While OAB cannot always be prevented, several modifiable lifestyle factors reduce the risk of developing the condition or attenuate symptom severity:

11. Recent Research

Vibegron (Vibegron 75 mg, Gemtesa): Approved by the FDA in 2020, vibegron is a highly selective beta-3 agonist with a favorable drug-interaction profile compared to mirabegron, particularly relevant in OAB patients taking tamsulosin (an alpha-1 blocker commonly used for BPH). The EMPOWUR trial demonstrated significant reductions in urgency incontinence episodes, urinary urgency, and micturition frequency versus placebo, with efficacy maintained at 52 weeks in the open-label extension. Vibegron does not inhibit CYP2D6 and does not raise blood pressure, expanding its use in patients with cardiovascular comorbidities.

Combination mirabegron plus solifenacin (SYNERGY trial): The SYNERGY phase 3 randomized controlled trial evaluated combination therapy with mirabegron 25 mg or 50 mg plus solifenacin 5 mg versus either agent alone in 3527 patients with OAB. The combination of mirabegron 50 mg plus solifenacin 5 mg achieved statistically superior reductions in micturition frequency, urgency incontinence episodes, and urgency severity versus either monotherapy, with a safety and tolerability profile not significantly worse than solifenacin alone. This combination is now incorporated into guideline algorithms for patients with inadequate response to monotherapy.

Transcranial magnetic stimulation (TMS) for central sensitization: Emerging evidence positions OAB, particularly refractory idiopathic OAB, within the spectrum of centrally sensitized syndromes. TMS targeting the dorsomedial prefrontal cortex and anterior cingulate cortex — regions implicated in descending inhibitory control of the micturition reflex — has produced statistically significant reductions in urgency and frequency in pilot trials. The mechanism is hypothesized to involve modulation of corticoreticulospinal inhibitory pathways that govern supraspinal suppression of detrusor overactivity.

Intravesical botulinum toxin versus SNM: The ABC (Anticholinergic versus Botulinum toxin Comparison) and ROSETTA (Refractory Overactive Bladder: Sacral Neuromodulation versus Botulinum Toxin Assessment) trials directly compared therapeutic approaches in anticholinergic-refractory OAB. ROSETTA demonstrated comparable efficacy between SNM and onabotulinumtoxinA at 6 months, with SNM showing greater durability at 24 months and botulinum toxin associated with higher rates of urinary tract infection and need for self-catheterization. Patient preference and functional capacity for self-catheterization guide treatment selection between these options.

12. References

  1. Abrams P, Cardozo L, Fall M, et al., 2002 — PMID: 11857671 — ICS standardisation of lower urinary tract function terminology.
  2. Coyne KS, Sexton CC, Vats V, et al., 2011 — PMID: 21944179 — National community prevalence of OAB in the US stratified by sex and age.
  3. Gormley EA, Lightner DJ, Burgio KL, et al., 2012 — PMID: 22857783 — AUA/SUFU guideline for diagnosis and treatment of OAB (non-neurogenic) in adults.
  4. Chapple CR, Kaplan SA, Mitcheson D, et al., 2013 — PMID: 23195283 — Phase 3 study of mirabegron (beta-3 agonist) 12-month safety and efficacy in OAB.
  5. Peters KM, Carrico DJ, Perez-Marrero RA, et al., 2010 — PMID: 20303107 — Randomized trial of percutaneous tibial nerve stimulation versus sham in OAB.
  6. Brubaker L, Richter HE, Visco A, et al., 2008 — PMID: 18295274 — Refractory idiopathic urge urinary incontinence and botulinum A injection.
  7. Nitti VW, Dmochowski R, Herschorn S, et al., 2013 — PMID: 23298662 — OnabotulinumtoxinA for treatment of patients with OAB and urinary incontinence.
  8. Burgio KL, Goode PS, Locher JL, et al., 2002 — PMID: 11978122 — Behavioral training with and without biofeedback for urge incontinence in older women.
  9. Dmochowski R, Chapple C, Nitti VW, et al., 2010 — PMID: 20483155 — Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder.
  10. Wyndaele M, Wyndaele JJ, 2004 — PMID: 15239759 — Incidence, prevalence and epidemiology of OAB in general practice.
  11. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM, 2005 — PMID: 15794793 — Improved quality of life in OAB patients treated with solifenacin.
  12. Cartwright R, Cardozo L, 2007 — PMID: 17532152 — Transient urethral catheterisation: minimising the risks.

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents